GeneFab was formed in 2023 with a vision to combine industry leading expertise in synthetic biology with advanced cGMP capabilities to accelerate the development and commercialization of genetic medicines. GeneFab spins out from more than seven years at Senti Biosciences as the manufacturing and CMC arm of an innovative drug maker. Combining R&D collaboration, CDMO capabilities, drug development, and regulatory expertise is a key differentiator for GeneFab to support clients from early development to clinical and commercial manufacturing. The team is led by CEO Philip Lee who brings 20 years of experience as a biotech innovator and was most recently Co-Founder and CTO of Senti. GeneFab employs over 90 employees with a collective experience of 350+ years developing cell and gene therapies from discovery to commercialization.
Press Releases
Products